BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1016 related articles for article (PubMed ID: 24487050)

  • 21. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
    Ting DS; Ng WY; Ng SR; Tan SP; Yeo IY; Mathur R; Chan CM; Tan AC; Tan GS; Wong TY; Cheung CM
    Am J Ophthalmol; 2016 Apr; 164():128-36.e1. PubMed ID: 26743619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
    Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
    Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
    Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
    Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
    Mathew R; Richardson M; Sivaprasad S
    Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Oct; 156(4):652-60. PubMed ID: 23891333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Choi KE; Hwang SY; Kim SW; Huh K
    BMC Ophthalmol; 2016 Mar; 16():25. PubMed ID: 26951107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation between changes in foveal choroidal thickness and 1-year results of ranibizumab therapy for polypoidal choroidal vasculopathy.
    Hikichi T; Kitamei H; Shioya S; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H
    Br J Ophthalmol; 2014 Sep; 98(9):1201-4. PubMed ID: 24723615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection.
    Lee JE; Kim HW; Lee SJ; Lee JE
    Retina; 2015 May; 35(5):999-1006. PubMed ID: 25590857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up.
    Marques IP; Fonseca P; Luz Cachulo M; Pires I; Figueira J; Faria de Abreu JR; Silva R
    Ophthalmologica; 2013; 229(3):158-67. PubMed ID: 23485818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Kawasaki R; Sekiryu T; Okada AA; Iida T
    Am J Ophthalmol; 2015 Apr; 159(4):627-33. PubMed ID: 25555799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Choroidal Topographic Changes by Swept-Source Optical Coherence Tomography After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Razavi S; Souied EH; Darvizeh F; Querques G
    Am J Ophthalmol; 2015 Nov; 160(5):1006-13. PubMed ID: 26275471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
    Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
    Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.